In a report released today, Justin Smith from Bernstein maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Shares of AstraZeneca PLC (LON:AZN – Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of £114.30 ($145.26) and traded as high ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Q4 2024 Earnings Call Transcript February 28, 2025 Gem Hopkins: Good morning and good afternoon, everyone. Thank you for ...

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sigma Planning Corp reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.0% during the fourth quarter, according to its most recent disclosure with the Securities and ...

Astrazeneca (AZN) ended the recent trading session at $76.21, demonstrating a +0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.59%.